Metagenomi, Inc. (MGX) Stock Forecast
MGX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $7.00 average of analyst targets
- Upside to target
- +792.9% from the latest close
- Next earnings
- November 10, 2026 EPS estimate $-0.74
- 52-week range
- $0.78 – $3.35
MGX analyst ratings
5 analystsNumber of analysts at each rating.
MGX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MGX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.62 | −$0.75 | −$0.55 | −$0.55 | −12.3% | 4 |
| Current fiscal year (FY2026) | −$2.42 | −$2.53 | −$2.16 | −$2.36 | −2.4% | 4 |
| Next fiscal year (FY2027) | −$1.83 | −$2.30 | −$1.56 | −$2.42 | +24.1% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MGX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.1M | $0 | $4.0M | −76.2% | 5 |
| Current fiscal year (FY2026) | $5.1M | $991,000 | $9.0M | −79.7% | 5 |
| Next fiscal year (FY2027) | $7.5M | $0 | $16.8M | +46.1% | 5 |
MGX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MGX revenue: reported and forecast
MGX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.52 | −$0.50 | −$0.50 | −$0.62 | +19.9% | 0 up · 3 down |
| Current fiscal year (FY2026) | −$2.11 | −$2.11 | −$2.16 | −$2.16 | −$2.42 | +14.6% | 0 up · 3 down |
| Next fiscal year (FY2027) | −$1.47 | −$1.47 | −$2.12 | −$2.12 | −$1.83 | +24.8% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MGX earnings surprises
Reported EPS vs the consensus estimate for the last 11 quarters; MGX beat in 5 of 11.
What analysts expect from MGX
5 analysts cover Metagenomi; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.00, 792.9% above the latest close of $0.78. Analysts expect earnings of −$2.42 per share for FY2026, −2.4% from a year earlier. For FY2027 the average estimate is −$1.83 per share on revenue of $7.5 million. Metagenomi beat the EPS estimate in 5 of the last 11 quarters.
Related: MGX income statement, MGX key metrics, MGX chart. See the MGX stock overview for the latest quote and news.
MGX forecast FAQ
What is Metagenomi's price target?
The average analyst price target for Metagenomi is $7.00, 792.9% above the latest close of $0.78.
Is Metagenomi a buy, hold or sell?
Of 5 analysts covering Metagenomi, 4 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Metagenomi's EPS forecast?
Analysts forecast −$2.42 per share for FY2026 (range −$2.53 to −$2.16); for FY2027 the estimate is −$1.83.
What is Metagenomi's revenue forecast?
The average revenue estimate for FY2026 is $5.1 million, growth of −79.7%; for FY2027 it is $7.5 million.
When does Metagenomi report earnings?
Metagenomi is expected to report results for the quarter ending September 30, 2026 on November 10, 2026; the EPS estimate is $-0.74.
Does Metagenomi usually beat earnings estimates?
Metagenomi reported EPS at or above the analyst estimate in 5 of the last 11 quarters.